ES2748805T3 - Composiciones de cicatrizacion de heridas mejoradas que comprenden microesferas - Google Patents
Composiciones de cicatrizacion de heridas mejoradas que comprenden microesferas Download PDFInfo
- Publication number
- ES2748805T3 ES2748805T3 ES13838041T ES13838041T ES2748805T3 ES 2748805 T3 ES2748805 T3 ES 2748805T3 ES 13838041 T ES13838041 T ES 13838041T ES 13838041 T ES13838041 T ES 13838041T ES 2748805 T3 ES2748805 T3 ES 2748805T3
- Authority
- ES
- Spain
- Prior art keywords
- wound
- pharmaceutical composition
- microspheres
- polystyrene microspheres
- specific gravity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 138
- 239000000203 mixture Substances 0.000 title claims description 77
- 230000029663 wound healing Effects 0.000 title description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 92
- 239000004793 Polystyrene Substances 0.000 claims abstract description 89
- 229920002223 polystyrene Polymers 0.000 claims abstract description 89
- 230000005484 gravity Effects 0.000 claims abstract description 57
- 239000002562 thickening agent Substances 0.000 claims abstract description 40
- 239000000243 solution Substances 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 33
- 239000000815 hypotonic solution Substances 0.000 claims abstract description 27
- 208000027418 Wounds and injury Diseases 0.000 claims description 137
- 206010052428 Wound Diseases 0.000 claims description 134
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 63
- 239000008215 water for injection Substances 0.000 claims description 40
- 235000011187 glycerol Nutrition 0.000 claims description 23
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 11
- 239000012153 distilled water Substances 0.000 claims description 10
- 208000025865 Ulcer Diseases 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 231100000397 ulcer Toxicity 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 208000000558 Varicose Ulcer Diseases 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 3
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- 208000002847 Surgical Wound Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
- 239000011780 sodium chloride Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 16
- 238000009472 formulation Methods 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 230000035876 healing Effects 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000004075 alteration Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 108010039918 Polylysine Proteins 0.000 description 3
- 102000007327 Protamines Human genes 0.000 description 3
- 108010007568 Protamines Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000011162 core material Substances 0.000 description 3
- -1 for example Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 208000008960 Diabetic foot Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010015943 Eye inflammation Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 239000003181 biological factor Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 210000004744 fore-foot Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940048914 protamine Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- WLZPCFOGJNCCRJ-UHFFFAOYSA-M 4-ethenyl-1-ethylpyridin-1-ium;bromide Chemical compound [Br-].CC[N+]1=CC=C(C=C)C=C1 WLZPCFOGJNCCRJ-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010006797 Burns first degree Diseases 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010012679 Diabetic neuropathic ulcer Diseases 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010050502 Neuropathic ulcer Diseases 0.000 description 1
- 208000000528 Pilonidal Sinus Diseases 0.000 description 1
- 206010035043 Pilonidal cyst Diseases 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/745—Polymers of hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261700362P | 2012-09-13 | 2012-09-13 | |
| PCT/IL2013/050774 WO2014041543A1 (en) | 2012-09-13 | 2013-09-12 | Improved wound healing compositions comprising microspheres |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2748805T3 true ES2748805T3 (es) | 2020-03-18 |
Family
ID=50277729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13838041T Active ES2748805T3 (es) | 2012-09-13 | 2013-09-12 | Composiciones de cicatrizacion de heridas mejoradas que comprenden microesferas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9370533B2 (enExample) |
| EP (1) | EP2895209B1 (enExample) |
| JP (1) | JP6104390B2 (enExample) |
| KR (1) | KR102200656B1 (enExample) |
| AU (1) | AU2013316718B2 (enExample) |
| BR (1) | BR112015005335B1 (enExample) |
| CA (1) | CA2883455C (enExample) |
| DK (1) | DK2895209T3 (enExample) |
| ES (1) | ES2748805T3 (enExample) |
| HR (1) | HRP20191804T1 (enExample) |
| HU (1) | HUE047212T2 (enExample) |
| LT (1) | LT2895209T (enExample) |
| MX (1) | MX359713B (enExample) |
| PL (1) | PL2895209T3 (enExample) |
| PT (1) | PT2895209T (enExample) |
| RS (1) | RS59410B1 (enExample) |
| WO (1) | WO2014041543A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6893877B2 (ja) * | 2014-10-29 | 2021-06-23 | スペクトラル エムディー, インコーポレイテッドSpectral Md, Inc. | 組織を分類するための反射モードマルチスペクトル時間分解型光学イメージングの方法および装置 |
| WO2018160963A1 (en) | 2017-03-02 | 2018-09-07 | Spectral Md, Inc. | Machine learning systems and techniques for multispectral amputation site analysis |
| JP7261883B2 (ja) | 2018-12-14 | 2023-04-20 | スペクトラル エムディー，インコーポレイテッド | 創傷の評価、治癒予測および治療のための機械学習システム |
| KR102812782B1 (ko) | 2018-12-14 | 2025-05-23 | 스펙트랄 엠디, 인크. | 고정밀도 다중-애퍼쳐 스펙트럼 이미징을 위한 시스템 및 방법 |
| US10783632B2 (en) | 2018-12-14 | 2020-09-22 | Spectral Md, Inc. | Machine learning systems and method for assessment, healing prediction, and treatment of wounds |
| US10740884B2 (en) | 2018-12-14 | 2020-08-11 | Spectral Md, Inc. | System and method for high precision multi-aperture spectral imaging |
| JP2024514493A (ja) | 2021-03-30 | 2024-04-02 | スペクトラル エムディー，インコーポレイテッド | 多重化照明を利用したスナップショット型高精度マルチスペクトルイメージングシステムおよびその方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614310A (en) | 1994-11-04 | 1997-03-25 | Minnesota Mining And Manufacturing Company | Low trauma wound dressing with improved moisture vapor permeability |
| US5861149A (en) | 1997-06-04 | 1999-01-19 | Polyheal Ltd. | Methods for wound treatment |
| EP1041970B1 (en) * | 1998-10-23 | 2013-07-03 | Polyheal Ltd. | Compositions of microspheres for wound healing |
| MXPA03008109A (es) * | 2001-03-07 | 2003-12-12 | Pfizer Prod Inc | Moduladores de la actividad de receptores de quimiocinas. |
| US7465463B2 (en) | 2002-09-04 | 2008-12-16 | Polyheal, Ltd. | Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues |
| WO2007089902A2 (en) * | 2006-01-31 | 2007-08-09 | David Vachon | Compositions and methods for promoting the healing of tissue of multicellular organisms |
| GB0607774D0 (en) * | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
-
2013
- 2013-09-12 KR KR1020157009202A patent/KR102200656B1/ko active Active
- 2013-09-12 AU AU2013316718A patent/AU2013316718B2/en active Active
- 2013-09-12 DK DK13838041.5T patent/DK2895209T3/da active
- 2013-09-12 JP JP2015531687A patent/JP6104390B2/ja active Active
- 2013-09-12 PL PL13838041T patent/PL2895209T3/pl unknown
- 2013-09-12 MX MX2015002816A patent/MX359713B/es active IP Right Grant
- 2013-09-12 WO PCT/IL2013/050774 patent/WO2014041543A1/en not_active Ceased
- 2013-09-12 EP EP13838041.5A patent/EP2895209B1/en active Active
- 2013-09-12 ES ES13838041T patent/ES2748805T3/es active Active
- 2013-09-12 PT PT138380415T patent/PT2895209T/pt unknown
- 2013-09-12 CA CA2883455A patent/CA2883455C/en active Active
- 2013-09-12 BR BR112015005335-1A patent/BR112015005335B1/pt active IP Right Grant
- 2013-09-12 RS RSP20191288 patent/RS59410B1/sr unknown
- 2013-09-12 LT LT13838041T patent/LT2895209T/lt unknown
- 2013-09-12 HR HRP20191804TT patent/HRP20191804T1/hr unknown
- 2013-09-12 HU HUE13838041A patent/HUE047212T2/hu unknown
- 2013-09-12 US US14/427,747 patent/US9370533B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20191804T1 (hr) | 2019-12-27 |
| LT2895209T (lt) | 2019-10-25 |
| RS59410B1 (sr) | 2019-11-29 |
| US9370533B2 (en) | 2016-06-21 |
| PT2895209T (pt) | 2019-10-28 |
| HUE047212T2 (hu) | 2020-04-28 |
| BR112015005335A2 (pt) | 2017-07-04 |
| KR20150082207A (ko) | 2015-07-15 |
| EP2895209A1 (en) | 2015-07-22 |
| KR102200656B1 (ko) | 2021-01-11 |
| BR112015005335B1 (pt) | 2020-03-10 |
| MX359713B (es) | 2018-10-08 |
| JP2015528492A (ja) | 2015-09-28 |
| JP6104390B2 (ja) | 2017-03-29 |
| AU2013316718A1 (en) | 2015-03-12 |
| WO2014041543A1 (en) | 2014-03-20 |
| HK1212638A1 (en) | 2016-06-17 |
| CA2883455A1 (en) | 2014-03-20 |
| EP2895209A4 (en) | 2016-04-20 |
| PL2895209T3 (pl) | 2020-01-31 |
| AU2013316718B2 (en) | 2016-09-29 |
| EP2895209B1 (en) | 2019-07-17 |
| MX2015002816A (es) | 2015-05-15 |
| BR112015005335A8 (pt) | 2018-01-30 |
| US20150231170A1 (en) | 2015-08-20 |
| CA2883455C (en) | 2020-01-28 |
| DK2895209T3 (da) | 2019-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2763524T3 (es) | Composiciones que comprenden fibras obtenidas electrohidrodinámicamente para la administración de dosis específicas de una sustancia activa a la piel o la mucosa | |
| ES2918452T3 (es) | Composiciones hemostáticas y regímenes terapéuticos | |
| ES2828711T3 (es) | Formulaciones de peróxido y métodos y aplicadores para usar las mismas | |
| AU2013316718B2 (en) | Improved wound healing compositions comprising microspheres | |
| BRPI0716270A2 (pt) | bandagem de ferida seca e sistema de distribuiÇço de fÁrmaco | |
| CN105142728B (zh) | 用于治疗表面创伤的组合物和方法 | |
| ES2932550T3 (es) | Composiciones estimulantes de células madre y métodos para tratar el melasma | |
| ES2860578T3 (es) | Composición para su uso en la reducción de la formación de costras y la promoción de la cicatrización. | |
| WO2019035705A2 (es) | Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel | |
| ES2657598T3 (es) | Preparación para el tratamiento de heridas y llagas que comprende hipoclorito y aminoácidos | |
| ES2404156T3 (es) | Una crema medicinal con ácido fusídico hecha utilizando fusidato de sodio e incorporando un biopolímero y el proceso para hacerla | |
| ES2335555T3 (es) | Uso de polietilenglicol en trastornos o enfermedades topicas relacionadas con la inflamacion y en cicatrizacion de heridas. | |
| ES2941360T3 (es) | Composiciones antihemorrágicas | |
| CN109996553A (zh) | 用于在内窥镜剥离术后预防食管狭窄的自组装肽基质 | |
| ES2251623T3 (es) | Dispositivo de cuidado de heridas. | |
| ES2887410T3 (es) | Utilización de compuestos oligosacáridos para tratar heridas en pacientes diabéticos con arteriopatías | |
| ES2216515T3 (es) | Composicion no solida para aplicacion local que comprende glicerol y un extracto de alchemilla vulgaris. | |
| WO2009077635A2 (es) | Composición antiinflamatoria, antiedematosa y antieritematosa, procedimiento de obtención y usos | |
| WO2023187632A1 (en) | Composition, application of the composition, cosmetic preparation hydrogel bio-mask in the form of a compress, method of manufacturing the preparation | |
| WO2004089406A1 (es) | Composición tópica en forma de gel para el tratamiento de quemaduras de la piel | |
| Simoes et al. | Lipid-based nanocarriers for Cutaneous Leishmaniais and Buruli Ulcer management | |
| ES2606947T3 (es) | Composición para combatir epistaxis | |
| RU2473349C1 (ru) | Фармацевтическая композиция для лечения ожогов | |
| ES2932359T3 (es) | Formulación basada en N-acetilcisteína y urea para el tratamiento de trastornos dermatológicos | |
| WO2017220845A1 (es) | Composiciones para el tratamiento de estrías y úlceras de origen isquémico |